a month ago
SRRK
AnalystsTessa RomeroTessa Romero's Stock Forecasts
AnalystsTessa Romero
Sectors:
Industries:
Analyst Ranking
Top 19%
#1045 out of 5548 analysts
Average Return
+10.02%
Win Rate
36%31 out of 85
Risk vs Reward
Poor
Good
Tessa Romero's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Scholar Rock Holding CorpSRRK | +397.74% | $7.07 | $35.19 | 2024-10-03 - 2025-10-02 | Strong Buy |
Dyne Therapeutics IncDYN | +307.09% | $10.58 | $43.07 | 2023-08-09 - 2024-08-08 | Strong Buy |
Edgewise Therapeutics IncEWTX | +219.64% | $13.80 | $44.11 | 2025-08-19 - 2026-08-18 | Strong Buy |
Biohaven LtdBHVN | +174.33% | $14.65 | $40.19 | 2023-01-04 - 2024-01-03 | Strong Buy |
Edgewise Therapeutics IncEWTX | +132.39% | $7.75 | $18.01 | 2023-06-30 - 2024-06-28 | Strong Buy |
Tessa Romero Analyst Color
Get additional color on Tessa Romero's coverage of popular stocks
2 months ago
EWTX
2 months ago
SRRK
2 months ago
CYTK
5 months ago
OCS
7 months ago
EWTX
7 months ago
SRRK
8 months ago
ACAD
10 months ago
XENE
a year ago
XENE
a year ago
SRRK
a year ago
EWTX
2 years ago
BHVN
2 years ago
CYTK
3 years ago
BHVN
Tessa Romero's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Adarx Pharmaceuticals IncADRX | 1 | Strong Buy | $38.00 | +115.54% | Initiates Coverage On | 5 days ago |
Eyepoint IncEYPT | 5 | Strong Sell | N/A | N/A | Downgrades | 5 days ago |
Praxis Precision Medicines IncPRAX | 1 | Strong Buy | $700.00 | +176.72% | Initiates Coverage On | 9 days ago |
Wave Life Sciences IncWVE | 1 | Hold | N/A | N/A | Downgrades | a month ago |
Scholar Rock Holding CorpSRRK | 8 | Strong Buy | $70.00 | +68.72% | Maintains | a month ago |
Dyne Therapeutics IncDYN | 9 | Strong Sell | $10.00 | -35.98% | Downgrades | 2 months ago |
Edgewise Therapeutics IncEWTX | 12 | Strong Buy | $60.00 | +52.63% | Maintains | 2 months ago |
Septerna IncSEPN | 2 | Strong Buy | $48.00 | +18.78% | Maintains | 2 months ago |
Oculis Holding AgOCS | 4 | Strong Buy | $20.00 | +153.16% | Maintains | 2 months ago |
Upstream Bio IncUPB | 3 | Hold | $9.00 | +228.47% | Maintains | 2 months ago |
Cytokinetics IncCYTK | 9 | Strong Buy | $103.00 | +68.22% | Maintains | 2 months ago |
Agios Pharmaceuticals IncAGIO | 11 | Hold | $34.00 | -8.11% | Maintains | 3 months ago |
Lexeo Therapeutics IncLXEO | 3 | Strong Buy | $9.00 | +221.43% | Maintains | 4 months ago |
Xenon Pharmaceuticals IncXENE | 6 | Strong Buy | $82.00 | +132.03% | Maintains | 5 months ago |
Larimar Therapeutics IncLRMR | 1 | Strong Buy | $9.00 | +282.98% | Initiates Coverage On | 5 months ago |
Seaport Therapeutics IncSPTX | 1 | Strong Buy | $42.00 | +103.78% | Initiates Coverage On | 5 months ago |
Acadia Pharmaceuticals IncACAD | 12 | Strong Buy | $34.00 | +72.33% | Maintains | 8 months ago |
Biohaven LtdBHVN | 8 | Strong Buy | $15.00 | +8.07% | Maintains | a year ago |
Rocket Pharmaceuticals IncRCKT | 1 | Strong Sell | $263.00 | +11,384.72% | Downgrades | a year ago |
Neumora Therapeutics IncNMRA | 5 | Strong Sell | N/A | N/A | Downgrades | a year ago |
Seres Therapeutics IncMCRB | 2 | Strong Sell | N/A | N/A | Downgrades | 2 years ago |
Y Mabs Therapeutics IncYMAB | 5 | Strong Sell | $7.00 | N/A | Maintains | 3 years ago |
Global Blood Therapeutics IncGBT | 2 | Hold | $36.00 | N/A | Maintains | 4 years ago |
Orchard Therapeutics PLCORTX | 1 | Strong Buy | $150.00 | N/A | Assumes | 6 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.